Navigation Links
Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
Date:9/8/2008

arkets. Before Genitope, Mr. Vuko was executive vice president and chief financial officer at Incyte Corporation, also a public company, which raised over $600 million during his tenure.

Beth Anne Piper, M.D., vice president, clinical development brings 19 years of clinical industry experience to Zosano. An endocrinologist by training, her most recent experience was as senior director of medical affairs and clinical development at FibroGen, where she drove the global development programs for their anemia portfolio. Ms. Piper also held positions at Pfizer and Bristol-Myers Squibb. Previously Ms. Piper worked at the Hospital for Special Surgery and New York Hospital, where she focused on metabolic bone and osteoporosis diseases.

Stephen Worsley, vice president, business development has held several senior licensing and business development positions in the biotechnology industry. Most recently, Mr. Worsley was vice president of business development at Raven biotechnology. Prior to Raven, he held senior business development positions at Abgenix and Tripos, Inc., and has successfully executed both licensing and joint venture agreements.

Zosano PTH patch is a novel transdermal patch formulation of parathyroid hormone (PTH) for the treatment of established osteoporosis. This product recently completed a Phase II program studying the Zosano transdermal patch formulation versus injectable Forteo in 165 women with severe osteoporosis in multiple sites across North and South America. Top line results from this study are expected to be available by the end of third quarter, 2008. Detailed results from the study have been submitted for presentation at an upcoming medical meeting in the fall.

About Zosano Pharma, Inc.

Zosano Pharma, Inc. is a privately held pharmaceutical company developing a novel transdermal delivery technology for a broad range of therapeutic indications. Its lead clinical program is evaluating a parathyroid hormone (hPTH 1-
'/>"/>

SOURCE Zosano Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
2. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
3. China Biopharma, Inc. Announces New Plan of Operation
4. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
5. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
6. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
7. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Prominent academics, leaders of the biopharmaceutical ... 3rd at Genetic Rx, a networking conference of ... place at the Joseph B. Martin Conference Center ... present and future of genetic medicines—including siRNA, ASOs, ... well as the treatment of patients with rare ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 RURO, ... solutions provider, has released Limfinity® version 5.1.4. , ... projects of Limfinity® than ever in RURO’s 8 ... and minority framework enhancement. Limfinity® version 5.1.4 is ... above and beyond bug fixes! , Limfinity® 5.1.4 ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5Viruses' Advantage of Surprise is Lost 2
... SOUTH SAN FRANCISCO, Calif., March 14 ,Exelixis, Inc. (Nasdaq: ... its option to further develop and commercialize Exelixis,compound XL518, ... currently,in a phase 1 clinical trial. Under the terms ... to be responsible for the phase,1 clinical trial until ...
... R.P. Baker Distinguished Professor of Physics at Rensselaer Polytechnic ... Materials Research Society (MRS). The MRS has recognized Lu ... specifically his seminal contributions to the fundamental understanding of ... that MRS has named a class of fellows. Lu ...
... ,Cellectis SA (NYSE: ALCLS ), a ... today that it filed a patent infringement ... States District Court for the,Eastern District of ... that,by making and selling certain meganucleases, Precision ...
Cached Biology Technology:Option to Develop Exelixis Compound Exercised By Genentech 2Option to Develop Exelixis Compound Exercised By Genentech 3Option to Develop Exelixis Compound Exercised By Genentech 4Professor Toh-Ming Lu named fellow of the Materials Research Society 2Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 2Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 3Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology 4
(Date:11/5/2014)... – Kelly Redmond has dedicated his career to ... to a general audience. , As deputy director ... Center at Nevada,s Desert Research Institute, Redmond has ... management, application and dissemination of climate data to ... Fall Meeting in San Francisco on December 15-19, ...
(Date:11/4/2014)... Fla. (November 4, 2014) — Think about the way ... How do neighboring cells know that they are supposed ... how do these tissues find the correct place and ... answering these crucial questions. , In a new study, ... to communicate with their surrounding neighbors, at the head-trunk ...
(Date:11/3/2014)... 2014 Research and Markets has announced ... Technologies, Markets and Companies" to their offering. ... methods, which have already started to play an important role ... replacing the old fashioned bone marrow transplants. Role of cells ... to become a part of medical practice. Stem ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2The inside story: How the brain and skull stay together 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... far from a plodding Cretaceous era scavenger whose long tail only ... T. rex ,s athleticism (and its rear end) ... Scott Persons. His extensive research shows that powerful tail muscles made ... time. As Persons says, "contrary to earlier theories, ...
... molecules called microRNAs act together with hormones to control ... drugs might be able to prevent premature labor, researchers ... preclinical study. "With these findings, we understand better ... we might have the potential to manipulate it and ...
... PA, 15 November 2010 - A family history of Alzheimer,s ... a new study in Biological Psychiatry suggests that ... Alzheimer,s is the most common form of dementia in ... alone. In order to develop preventative treatments, it is necessary ...
Cached Biology News:T. rex's big tail was its key to speed and hunting prowess 2Tiny RNA molecules control labor, may be key to blocking premature birth 2Where did you get those eyes and that brain? 2
... scanning and positioning system is designed ... to be positioned or scanned with ... provides superior responsiveness compared to micropositioners ... (X or XY stage) are driven ...
For microscopy...
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... 'The DNAscope LM is a high quality ... technology for optimal background rejection and spatial resolution. ... is the only low cost microarray scanner that ... excitation sources. Main Features: Includes ...
Biology Products: